Literature DB >> 11326338

Autosomal dominant craniometaphyseal dysplasia is caused by mutations in the transmembrane protein ANK.

E Reichenberger1, V Tiziani, S Watanabe, L Park, Y Ueki, C Santanna, S T Baur, R Shiang, D K Grange, P Beighton, J Gardner, H Hamersma, S Sellars, R Ramesar, A C Lidral, A Sommer, C M Raposo do Amaral, R J Gorlin, J B Mulliken, B R Olsen.   

Abstract

Craniometaphyseal dysplasia (CMD) is a rare skeletal disorder characterized by progressive thickening and increased mineral density of craniofacial bones and abnormally developed metaphyses in long bones. Linkage studies mapped the locus for the autosomal dominant form of CMD to an approximately 5-cM interval on chromosome 5p, which is defined by recombinations between loci D5S810 and D5S1954. Mutational analysis of positional candidate genes was performed, and we describe herein three different mutations, in five different families and in isolated cases, in ANK, a multipass transmembrane protein involved in the transport of intracellular pyrophosphate into extracellular matrix. The mutations are two in-frame deletions and one in-frame insertion caused by a splicing defect. All mutations cluster within seven amino acids in one of the six possible cytosolic domains of ANK. These results suggest that the mutated protein has a dominant negative effect on the function of ANK, since reduced levels of pyrophosphate in bone matrix are known to increase mineralization.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11326338      PMCID: PMC1226118          DOI: 10.1086/320612

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  15 in total

1.  The gene for cherubism maps to chromosome 4p16.

Authors:  V Tiziani; E Reichenberger; C L Buzzo; S Niazi; N Fukai; M Stiller; H Peters; F M Salzano; C M Raposo do Amaral; B R Olsen
Journal:  Am J Hum Genet       Date:  1999-07       Impact factor: 11.025

Review 2.  Hypophosphatasia and the extracellular metabolism of inorganic pyrophosphate: clinical and laboratory aspects.

Authors:  A M Caswell; M P Whyte; R G Russell
Journal:  Crit Rev Clin Lab Sci       Date:  1991       Impact factor: 6.250

3.  A high-resolution physical and transcript map of the Cri du chat region of human chromosome 5p.

Authors:  D M Church; J Yang; M Bocian; R Shiang; J J Wasmuth
Journal:  Genome Res       Date:  1997-08       Impact factor: 9.043

4.  The gene for autosomal dominant craniometaphyseal dysplasia maps to chromosome 5p and is distinct from the growth hormone-receptor gene.

Authors:  P Nürnberg; S Tinschert; M Mrug; J Hampe; C R Müller; E Fuhrmann; H S Braun; A Reis
Journal:  Am J Hum Genet       Date:  1997-10       Impact factor: 11.025

5.  Role of the mouse ank gene in control of tissue calcification and arthritis.

Authors:  A M Ho; M D Johnson; D M Kingsley
Journal:  Science       Date:  2000-07-14       Impact factor: 47.728

6.  Mapping of the autosomal recessive (AR) craniometaphyseal dysplasia locus to chromosome region 6q21-22 and confirmation of genetic heterogeneity for mild AR spondylocostal dysplasia.

Authors:  P Iughetti; L G Alonso; W Wilcox; N Alonso; M R Passos-Bueno
Journal:  Am J Med Genet       Date:  2000-12-18

7.  Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST).

Authors:  W Balemans; M Ebeling; N Patel; E Van Hul; P Olson; M Dioszegi; C Lacza; W Wuyts; J Van Den Ende; P Willems; A F Paes-Alves; S Hill; M Bueno; F J Ramos; P Tacconi; F G Dikkers; C Stratakis; K Lindpaintner; B Vickery; D Foernzler; W Van Hul
Journal:  Hum Mol Genet       Date:  2001-03-01       Impact factor: 6.150

8.  Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein.

Authors:  M E Brunkow; J C Gardner; J Van Ness; B W Paeper; B R Kovacevich; S Proll; J E Skonier; L Zhao; P J Sabo; Y Fu; R S Alisch; L Gillett; T Colbert; P Tacconi; D Galas; H Hamersma; P Beighton; J Mulligan
Journal:  Am J Hum Genet       Date:  2001-02-09       Impact factor: 11.025

9.  Progressive ankylosis, a new skeletal mutation in the mouse.

Authors:  H O Sweet; M C Green
Journal:  J Hered       Date:  1981 Mar-Apr       Impact factor: 2.645

10.  Metaphyseal dysplasia, epiphyseal dysplasia, diaphyseal dysplasia, and related conditions. I. Familial metaphyseal dysplasia and craniometaphyseal dysplasia; their relation to leontiasis ossea and osteopetrosis; disorders of bone remodeling.

Authors:  W P JACKSON; F ALBRIGHT; G DREWRY; J HANELIN; M I RUBIN
Journal:  AMA Arch Intern Med       Date:  1954-12
View more
  61 in total

1.  It ANKH necessarily so.

Authors:  Michael T Collins; Manfred Boehm
Journal:  J Clin Endocrinol Metab       Date:  2011-01       Impact factor: 5.958

2.  Genetic and enzymatic analysis for two Japanese patients with idiopathic infantile arterial calcification.

Authors:  Chikahiko Numakura; Makoto Yamada; Daisuke Ariyasu; Akiko Maesaka; Hironori Kobayashi; Gen Nishimura; Masahiro Ikeda; Yukihiro Hasegawa
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

3.  Novel ANKH mutation in a patient with sporadic craniometaphyseal dysplasia.

Authors:  Allison Zajac; Seung-Hak Baek; Imad Salhab; Melissa A Radecki; Sukwha Kim; Hakon Hakonarson; Hyun-Duck Nah
Journal:  Am J Med Genet A       Date:  2010-03       Impact factor: 2.802

4.  Investigating ANKH and ENPP1 in Slovakian families with chondrocalcinosis.

Authors:  Ana Rita Couto; Yun Zhang; Andrew Timms; Jacome Bruges-Armas; Jorge Sequeiros; Matthew A Brown
Journal:  Rheumatol Int       Date:  2011-08-03       Impact factor: 2.631

5.  Craniometaphyseal Dysplasia: A review and novel oral manifestation.

Authors:  K Martin; S Nathwani; R Bunyan
Journal:  J Oral Biol Craniofac Res       Date:  2017-05-06

Review 6.  Sclerosing bone dysplasias: leads toward novel osteoporosis treatments.

Authors:  Igor Fijalkowski; Eveline Boudin; Geert Mortier; Wim Van Hul
Journal:  Curr Osteoporos Rep       Date:  2014-09       Impact factor: 5.096

Review 7.  Inflammation: a culprit for vascular calcification in atherosclerosis and diabetes.

Authors:  L Bessueille; D Magne
Journal:  Cell Mol Life Sci       Date:  2015-03-08       Impact factor: 9.261

8.  Induced pluripotent stem cell reprogramming by integration-free Sendai virus vectors from peripheral blood of patients with craniometaphyseal dysplasia.

Authors:  I-Ping Chen; Keiichi Fukuda; Noemi Fusaki; Akihiro Iida; Mamoru Hasegawa; Alexander Lichtler; Ernst J Reichenberger
Journal:  Cell Reprogram       Date:  2013-11-12       Impact factor: 1.987

9.  Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density.

Authors:  Liesbeth Van Wesenbeeck; Erna Cleiren; Jeppe Gram; Rodney K Beals; Olivier Bénichou; Domenico Scopelliti; Lyndon Key; Tara Renton; Cindy Bartels; Yaoqin Gong; Matthew L Warman; Marie-Christine De Vernejoul; Jens Bollerslev; Wim Van Hul
Journal:  Am J Hum Genet       Date:  2003-02-10       Impact factor: 11.025

10.  FGF2 stimulation of the pyrophosphate-generating enzyme, PC-1, in pre-osteoblast cells is mediated by RUNX2.

Authors:  Nan E Hatch; Yan Li; Renny T Franceschi
Journal:  J Bone Miner Res       Date:  2009-04       Impact factor: 6.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.